Back to ADC

ADC

Showing 6 study arms with grade ≥3 adverse event data (treatment-related and RT-related). Click a column header to sort.

Note on patient counts: some articles reported only percentages rather than absolute numbers. Where this occurred, the number of patients — including those with grade ≥3 adverse events — was derived by applying the reported percentage to the total arm size, which may produce a non-integer value. These figures have been rounded to the nearest integer for display.

1st Author⇅	Year⇅	Study Type⇅	Title⇅	DOI⇅	clinical trial number⇅	number of patients⇅	median/mean age⇅	median follow-up [months]⇅	tumor type⇅	treatment setting⇅	drug group⇅	drug name⇅	if other, please specify⇅	number of SBRT courses⇅	intracranial / extracranial⇅	treated site⇅	If other treated site, please specify⇅	median/mean total RT dose [Gy]⇅	minimum total RT dose [Gy]⇅	maximum total RT dose [Gy]⇅	median/mean number of fractions⇅	minimum number of fractions⇅	maximum number of fractions⇅	median/mean dose per fraction [Gy]⇅	minimum dose per fraction [Gy]⇅	maximum dose per fraction [Gy]⇅	toxicity type⇅	patients with acute G>=3 toxicity⇅	patients with late G>=3 toxicity⇅	patients with G>=3 toxicity, timing unspecified⇅	G>=3 AEs⇅	patients with G>=3 AEs⇅	details on G>=3 toxicity⇅	details on G>=3 toxicity in RT field⇅
Looman et al.	2026	Prospective	Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy	10.1001/jamanetworkopen.2025.53809	—	3	62	18.0	Breast cancer, Lung cancer, Prostate cancer, Colorectal cancer, Head and neck cancer, Esophagus cancer, Melanoma, Kidney cancer, Bladder cancer, Sarcoma, other	oligometastatic, metastatic	ADC	Trastuzumab Emtansine	—	Missing	intra-cranial	brain	—	—	—	—	Missing	1	10	—	—	—	RT-related	—	—	0	—	—	—	—
Alati et al.	2025	Retrospective	Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study	10.1016/j.ijrobp.2025.11.060	—	25	55.8	7.9	Breast cancer	any	ADC	Sacituzumab Govitecan	—	Missing	both	Missing	—	25	13	42	3	1	5	8	5	21	RT-related	—	—	1	any G3: 1 AE	any G3: 1 pt	any G3: nausea	any G3: nausea
Ippolito et al.	2025	Prospective	Breast CancerTrastuzumab-deruxtecan and radiotherapy: a safety sub-analysis of combart prospective cohort study	10.1093/oncolo/oyaf229	Missing	22	Missing	11.0	Breast cancer	any	ADC	Trastuzumab Deruxtecan	—	52	both	brain, lung, bone, other	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Missing	3	5	RT-related	0	1	—	late G3: 1 AE	late G3: 1 pt	late G3: radionecrosis	late G3: radionecrosis
Khatri et al.	2025	Retrospective	Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report	10.1007/s11060-025-05230-7	—	26	24	23.4	Breast cancer	metastatic	ADC	Sacituzumab Govitecan	—	135	intra-cranial	brain	—	24	16	30	Missing	1	5	Missing	5	24	Radiation necrosis	—	0	—	—	—	—	—
Lebow et al.	2025	Retrospective	Local Therapy for Isolated Central Nervous System Progression Among Patients Receiving Antibody-Drug Conjugate Therapy.	10.1016/j.adro.2025.101714	—	13	57.3	29.5	Breast cancer	metastatic	ADC	Sacituzumab Govitecan, Trastuzumab Deruxtecan, Trastuzumab Emtansine	—	13	intra-cranial	brain	—	21	21	23	1	1	3	21	9	21	RT-related	—	—	3	any G4: 5 AEs, any G5: 1 AE	any G4: 2 pts, any G5: 1 pt	any G4: Radiation necrosis, gait instability, any G5: intracranial hemorrhage	any G3: headache, aphasia, any G4: Radiation necrosis, gait instability, any G5: intracranial hemorrhage
Stumpf et al.	2019	Retrospective	Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4	10.1158/1078-0432.Ccr-18-2851	—	16	45	—	Breast cancer	metastatic	ADC	Trastuzumab Emtansine	—	Missing	intra-cranial	brain	—	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Missing	Radiation necrosis	—	—	6	—	—	clinically significant radiation necrosis was defined as neurologic symptoms warranting hospital admission and treatment.	clinically significant radiation necrosis was defined as neurologic symptoms warranting hospital admission and treatment.